ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
Abstract Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and...
Main Authors: | Mohamed I Saad, Sultan Alhayyani, Louise McLeod, Liang Yu, Mohammad Alanazi, Virginie Deswaerte, Ke Tang, Thierry Jarde, Julian A Smith, Zdenka Prodanovic, Michelle D Tate, Jesse J Balic, D Neil Watkins, Jason E Cain, Steven Bozinovski, Elizabeth Algar, Tomohiro Kohmoto, Hiromichi Ebi, Walter Ferlin, Christoph Garbers, Saleela Ruwanpura, Irit Sagi, Stefan Rose‐John, Brendan J Jenkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2019-04-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201809976 |
Similar Items
-
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
by: Yuta Adachi, et al.
Published: (2021-10-01) -
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
by: Enrico Gurreri, et al.
Published: (2023-05-01) -
The role of KRAS splice variants in cancer biology
by: Cristina Nuevo-Tapioles, et al.
Published: (2022-11-01) -
Unveiling the role of KRAS in tumor immune microenvironment
by: Miao Xu, et al.
Published: (2024-02-01) -
Synthetic Vulnerabilities in the KRAS Pathway
by: Marta Roman, et al.
Published: (2022-06-01)